Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
Hyper-IgM Syndrome, Ectodermal Dysplasia
About this trial
This is an observational trial for Hyper-IgM Syndrome focused on measuring CD40 Ligand, Nemo, Genetics, Hyper-IGM, Ectodermal Dysplasia, CVID, Hyper-IgM Syndrome, Primary Immune Deficiency Disorders, Common Variable Immune Deficiency
Eligibility Criteria
INCLUSION CRITERIA: All patients must have a known or suspected immune defect with hyper-IgM syndrome and/or disorders of immunoglobulin production. There will be no limit on age, sex, race, or disability. Normal volunteers must be healthy adults between the age of 18 and 70 years. All study participants enrolled on to this study must agree to allow PI to store research samples. Refusal to let PI store samples may lead to withdrawal fro this specific study. EXCLUSION CRITERIA: The presence of an acquired abnormality, which leads to immune defects, such as HIV, chemotherapy, and malignancy are general exclusion criteria. Refusal to let us store samples may lead to withdrawal from this specific study. Other factors, which are in the judgment of the Principal Investigator PI that may interfere with patient evaluation or determine to pose an added risk for study participants are also criteria for exclusion.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike